Live
FierceBiotechNovartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeoverLabiotechAdvancing corticosteroids and hormonal therapies for supply and scaleFierceBiotech‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliffLonza NewsSmall-Molecule CDMO Outlook: What Lies Ahead - DCAT Value Chain InsightsClinical OMICsPioneering Innovation in Transplant DiagnosticsFierceBiotechRoche nabs EU approval on label expansions for companion dx platformFierceBiotechGenentech executes another round of layoffs, with 3 VPs axedScienceLaser-boosted microscopes could reveal new drug targets, sharpen views inside cellsScienceThe ocean current that warms Europe may be more resilient than fearedClinical OMICsCyclana Bio Is Exploring the Extracellular Matrix to Treat EndometriosisFierceBiotechAI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data findsRoche MediaGenentech executes another round of layoffs, with 3 VPs axed - Fierce Biotech
BioPharma Dive Mar 13, 2026

Evotec, Vistagen lay off staff; Immutep shares collapse on study failure

Evotec, Vistagen lay off staff; Immutep shares collapse on study failure

Original
Body unavailable. Use the original source.